New methods for evaluating acute treatments in migraine.
The crescendo of activities in the field of migraine therapy, has led to the emergence of a class of molecules, the triptans, that are similar in terms of their activity on serotonin receptors, but which actually differ from one another, as each one has its own peculiar clinical profile. A careful examination of their clinical activity and their validation with objective methods may promote the wise use of each drug, make room for new products, and allow patients to make their own choices.